Zymeworks Inc (ZYME)

$25.31 +0.19 (0.76%)
Market Cap 1.78B
Revenue (ttm) 105.97M
Net Income (ttm) -81.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 20.53
Profit Margin -76.56%
Debt to Equity Ratio 0.00
Volume 442,300
Avg Vol 560,422
Day's Range N/A - N/A
Shares Out 70.96M
Stochastic %K 78%
Beta 1.15
Analysts Strong Sell
Price Target $40.25

Company Profile

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-sp...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 274 8744
Address:
108 Patriot Drive, Suite A, Middletown, United States
StarshipBlooper
StarshipBlooper Aug. 10 at 2:18 PM
$ZYME heading back to $30 and it won’t be long
0 · Reply
notreload_ai
notreload_ai Aug. 10 at 10:07 AM
Citi places $ZYME on 90-day upside watch with Buy rating and $37 target ahead of the Aug 25 FDA decision on zanidatamab for HER2+ GEA. https://notreload.xyz/xy/zymeworks-citi-flags-upside-catalyst-before-aug-25-fda/
0 · Reply
Nickhzap
Nickhzap Aug. 8 at 1:47 AM
$ZYME sheep boy has gotten awfully quiet
2 · Reply
buyoutorbust_
buyoutorbust_ Aug. 7 at 8:52 PM
$ZYME Roughly 85-90% chances of approval give or take? The asymmetrical setup here looks lovely.
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Aug. 6 at 9:15 PM
$ZYME lot of nice tidbits in that earnings. Co is really turning into a player
1 · Reply
Mikelonggggggggg
Mikelonggggggggg Aug. 6 at 6:02 PM
$ZYME
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Aug. 5 at 6:08 PM
$ZYME
1 · Reply
copytheinsider
copytheinsider Aug. 4 at 5:35 PM
$ZYME has an FDA decision coming up on August 25 for zanidatamab. If approved, Zymeworks is eligible to receive a $250 million milestone payment from Jazz, making this one of biotech's biggest August catalysts. Do you think the FDA approves?
1 · Reply
Boris_Badenov
Boris_Badenov Aug. 3 at 9:45 PM
$ZYME JAZZ earnings release/call affirmed ready to launch GEA on or before 8/25 (PDUFA). Reported $15.4 million in Ziihera revenues for 2Q26 (compared to $6 million 2Q25).
1 · Reply
BuyingSheep
BuyingSheep Aug. 3 at 2:43 PM
$ZYME everything is green today except this turd. 💩
1 · Reply
Latest News on ZYME
Zymeworks price target raised to $44 from $40 at B. Riley

2026-08-10T12:20:26.000Z - 7 days ago

Zymeworks price target raised to $44 from $40 at B. Riley

Citi adds ‘upside 90-day catalyst watch’ on Zymeworks in FDA decision

2026-08-10T09:30:42.000Z - 7 days ago

Citi adds ‘upside 90-day catalyst watch’ on Zymeworks in FDA decision

Zymeworks price target raised to $32 from $31 at Truist

2026-08-07T14:25:33.000Z - 10 days ago

Zymeworks price target raised to $32 from $31 at Truist

Zymeworks price target lowered to $46 from $47 at Stifel

2026-08-07T13:16:08.000Z - 10 days ago

Zymeworks price target lowered to $46 from $47 at Stifel

Zymeworks price target raised to $40 from $37 at Wells Fargo

2026-08-07T11:25:53.000Z - 10 days ago

Zymeworks price target raised to $40 from $37 at Wells Fargo

Zymeworks reports Q2 EPS (62c), consensus (55c)

2026-08-06T21:40:35.000Z - 11 days ago

Zymeworks reports Q2 EPS (62c), consensus (55c)

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Aug 6, 2026, 4:05 PM EDT - 11 days ago

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Zymeworks Quarterly report: Q2 2026

Aug 6, 2026, 4:00 PM EDT - 11 days ago

Zymeworks Quarterly report: Q2 2026

Zymeworks Earnings release: Q2 2026

Aug 6, 2026, 4:00 PM EDT - 11 days ago

Zymeworks Earnings release: Q2 2026

Zymeworks price target raised to $51 from $46 at H.C. Wainwright

2026-08-05T16:55:23.000Z - 12 days ago

Zymeworks price target raised to $51 from $46 at H.C. Wainwright

JAZZ JNJ

Zymeworks management to meet with B. Riley

2026-07-21T18:55:11.000Z - 27 days ago

Zymeworks management to meet with B. Riley

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

Jul 16, 2026, 6:00 AM EDT - 4 weeks ago

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

Zymeworks price target raised to $31 from $28 at Truist

2026-07-07T13:21:36.000Z - 5 weeks ago

Zymeworks price target raised to $31 from $28 at Truist

Zymeworks price target raised to $37 from $34 at Wells Fargo

2026-06-30T10:25:21.000Z - 6 weeks ago

Zymeworks price target raised to $37 from $34 at Wells Fargo

Zymeworks price target raised to $37 from $35 at Citi

2026-06-30T09:45:22.000Z - 6 weeks ago

Zymeworks price target raised to $37 from $35 at Citi

TBPH

Zymeworks Transcript: M&A announcement

Jun 29, 2026, 8:30 AM EDT - 7 weeks ago

Zymeworks Transcript: M&A announcement

Zymeworks Press release: M&A announcement

Jun 29, 2026, 8:30 AM EDT - 7 weeks ago

Zymeworks Press release: M&A announcement

Zymeworks Slides: M&A announcement

Jun 29, 2026, 8:30 AM EDT - 7 weeks ago

Zymeworks Slides: M&A announcement

M&A News: Biotech Group Zymeworks Buys Lung Disease-Fighting Peer Theravance for $1B

2026-06-29T10:33:25.000Z - 7 weeks ago

M&A News: Biotech Group Zymeworks Buys Lung Disease-Fighting Peer Theravance for $1B

TBPH

Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash

2026-06-29T10:15:32.000Z - 7 weeks ago

Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash

TBPH

Zymeworks strikes $929 million deal for Theravance Biopharma

Jun 29, 2026, 6:13 AM EDT - 7 weeks ago

Zymeworks strikes $929 million deal for Theravance Biopharma

TBPH

Zymeworks to acquire Theravance Biopharma for $17.00 per share, or $929M

2026-06-29T10:10:41.000Z - 7 weeks ago

Zymeworks to acquire Theravance Biopharma for $17.00 per share, or $929M

TBPH

Zymeworks to acquire Theravance Biopharma for $17.00 per share

2026-06-29T10:06:12.000Z - 7 weeks ago

Zymeworks to acquire Theravance Biopharma for $17.00 per share

TBPH

Zymeworks to Acquire Theravance Biopharma, Inc.

Jun 29, 2026, 6:00 AM EDT - 7 weeks ago

Zymeworks to Acquire Theravance Biopharma, Inc.

Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery

Jun 18, 2026, 8:00 AM EDT - 2 months ago

Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery

Zymeworks presents new clinical data on Phase 1 study of ZW191

2026-06-14T23:15:05.000Z - 2 months ago

Zymeworks presents new clinical data on Phase 1 study of ZW191

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Jun 14, 2026, 6:05 PM EDT - 2 months ago

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks assumed with a Buy at Truist

2026-06-09T12:13:20.000Z - 2 months ago

Zymeworks assumed with a Buy at Truist

Zymeworks Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 8:45 AM EDT - 2 months ago

Zymeworks Transcript: Jefferies Global Healthcare Conference 2026

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

May 14, 2026, 4:05 PM EDT - 3 months ago

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Zymeworks Announces Participation in Upcoming Investor Conferences

May 13, 2026, 6:00 AM EDT - 3 months ago

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Zymeworks Earnings Call Transcript: Q1 2026

Zymeworks Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Zymeworks Earnings release: Q1 2026

Zymeworks Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Zymeworks Slides: Q1 2026

Zymeworks Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Zymeworks Quarterly report: Q1 2026

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 4:05 PM EDT - 3 months ago

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Apr 21, 2026, 5:30 PM EDT - 4 months ago

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Zymeworks Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 21, 2026, 9:30 AM EDT - 4 months ago

Zymeworks Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Apr 17, 2026, 3:00 PM EDT - 4 months ago

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

Apr 16, 2026, 6:00 AM EDT - 4 months ago

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

Zymeworks Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 10:15 AM EDT - 4 months ago

Zymeworks Transcript: 25th Annual Needham Virtual Healthcare Conference

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

Apr 9, 2026, 6:00 AM EDT - 4 months ago

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

Apr 1, 2026, 6:00 AM EDT - 4 months ago

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

Mar 30, 2026, 6:00 AM EDT - 5 months ago

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Mar 18, 2026, 7:46 AM EDT - 5 months ago

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Mar 17, 2026, 5:02 PM EDT - 5 months ago

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Zymeworks Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 10:10 AM EDT - 5 months ago

Zymeworks Transcript: The Citizens Life Sciences Conference 2026

Zymeworks Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 3:00 PM EDT - 5 months ago

Zymeworks Transcript: Leerink Global Healthcare Conference 2026

Zymeworks Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 2:30 PM EST - 6 months ago

Zymeworks Transcript: TD Cowen 46th Annual Health Care Conference

Zymeworks Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:30 AM EST - 6 months ago

Zymeworks Earnings Call Transcript: Q4 2025

Zymeworks Earnings release: Q4 2025

Mar 2, 2026, 8:30 AM EST - 6 months ago

Zymeworks Earnings release: Q4 2025

Zymeworks Slides: Q4 2025

Mar 2, 2026, 8:30 AM EST - 6 months ago

Zymeworks Slides: Q4 2025

Zymeworks Annual report: Q4 2025

Mar 2, 2026, 8:30 AM EST - 6 months ago

Zymeworks Annual report: Q4 2025

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Mar 2, 2026, 6:01 AM EST - 6 months ago

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 6:00 AM EST - 6 months ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Zymeworks Slides: Corporate presentation

Feb 27, 2026, 7:00 AM EST - 6 months ago

Zymeworks Slides: Corporate presentation

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Feb 12, 2026, 6:00 AM EST - 6 months ago

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Zymeworks Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:00 PM EST - 7 months ago

Zymeworks Transcript: 44th Annual J.P. Morgan Healthcare Conference

Zymeworks Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:00 PM EST - 7 months ago

Zymeworks Slides: 44th Annual J.P. Morgan Healthcare Conference

Zymeworks Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 7 months ago

Zymeworks Slides: Corporate presentation

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Jan 12, 2026, 6:00 AM EST - 7 months ago

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Jan 11, 2026, 6:00 PM EST - 7 months ago

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Jan 6, 2026, 1:34 PM EST - 7 months ago

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Zymeworks Announces Participation in Upcoming Conferences

Dec 2, 2025, 4:05 PM EST - 9 months ago

Zymeworks Announces Participation in Upcoming Conferences

Zymeworks Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 10:00 AM EST - 9 months ago

Zymeworks Transcript: Evercore ISI 8th Annual HealthCONx Conference

Zymeworks Transcript: Investor Update

Nov 18, 2025, 8:30 AM EST - 9 months ago

Zymeworks Transcript: Investor Update

Zymeworks Press release: Investor Update

Nov 18, 2025, 8:30 AM EST - 9 months ago

Zymeworks Press release: Investor Update

Zymeworks Slides: Investor Update

Nov 18, 2025, 8:30 AM EST - 9 months ago

Zymeworks Slides: Investor Update

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Nov 18, 2025, 1:01 AM EST - 9 months ago

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Nov 18, 2025, 1:00 AM EST - 9 months ago

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

Nov 17, 2025, 8:10 AM EST - 9 months ago

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

JAZZ

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Nov 17, 2025, 6:00 AM EST - 9 months ago

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Zymeworks Proxy statement: Proxy filing

Nov 10, 2025, 7:00 AM EST - 10 months ago

Zymeworks Proxy statement: Proxy filing

Zymeworks Proxy statement: Proxy filing

Nov 10, 2025, 7:00 AM EST - 10 months ago

Zymeworks Proxy statement: Proxy filing

Zymeworks Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Zymeworks Earnings Call Transcript: Q3 2025

Zymeworks Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Zymeworks Earnings release: Q3 2025

Zymeworks Slides: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Zymeworks Slides: Q3 2025

Zymeworks Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Zymeworks Quarterly report: Q3 2025

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 10 months ago

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Zymeworks Transcript: Study Result

Oct 23, 2025, 3:30 PM EDT - 10 months ago

Zymeworks Transcript: Study Result

Zymeworks Press release: Study Result

Oct 23, 2025, 3:30 PM EDT - 10 months ago

Zymeworks Press release: Study Result

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Oct 23, 2025, 12:30 PM EDT - 10 months ago

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Zymeworks Slides: Corporate Presentation

Oct 22, 2025, 6:00 PM EDT - 10 months ago

Zymeworks Slides: Corporate Presentation

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Oct 16, 2025, 6:00 AM EDT - 10 months ago

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Oct 13, 2025, 4:00 PM EDT - 11 months ago

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Oct 9, 2025, 8:30 AM EDT - 11 months ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

INM

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Oct 9, 2025, 6:00 AM EDT - 11 months ago

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Zymeworks Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Zymeworks halts development of cancer drug after trial setback

Sep 2, 2025, 6:18 AM EDT - 1 year ago

Zymeworks halts development of cancer drug after trial setback

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Sep 2, 2025, 6:00 AM EDT - 1 year ago

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Aug 11, 2025, 6:00 AM EDT - 1 year ago

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Zymeworks Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Earnings Call Transcript: Q2 2025

Zymeworks Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Quarterly report: Q2 2025

Zymeworks Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Earnings release: Q2 2025

Zymeworks Slides: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Slides: Q2 2025

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Jul 28, 2025, 6:00 AM EDT - 1 year ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Jul 17, 2025, 6:00 AM EDT - 1 year ago

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Zymeworks Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Zymeworks Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

May 30, 2025, 6:00 AM EDT - 1 year ago

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

May 22, 2025, 5:00 PM EDT - 1 year ago

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

May 19, 2025, 4:15 PM EDT - 1 year ago

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Zymeworks Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Earnings Call Transcript: Q1 2025

Zymeworks Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Quarterly report: Q1 2025

Zymeworks Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Earnings release: Q1 2025

Zymeworks Slides: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Slides: Q1 2025

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 1 year ago

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Apr 25, 2025, 1:00 PM EDT - 1 year ago

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Apr 21, 2025, 6:00 AM EDT - 1 year ago

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 17, 2025, 6:00 AM EDT - 1 year ago

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Zymeworks Earnings Call Transcript: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Zymeworks Earnings Call Transcript: Q4 2024

Zymeworks Annual report: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Zymeworks Annual report: Q4 2024

Zymeworks Earnings release: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Zymeworks Earnings release: Q4 2024

Zymeworks Slides: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Zymeworks Slides: Q4 2024

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 4:05 PM EST - 1 year ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Feb 26, 2025, 6:00 AM EST - 1 year ago

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

StarshipBlooper
StarshipBlooper Aug. 10 at 2:18 PM
$ZYME heading back to $30 and it won’t be long
0 · Reply
notreload_ai
notreload_ai Aug. 10 at 10:07 AM
Citi places $ZYME on 90-day upside watch with Buy rating and $37 target ahead of the Aug 25 FDA decision on zanidatamab for HER2+ GEA. https://notreload.xyz/xy/zymeworks-citi-flags-upside-catalyst-before-aug-25-fda/
0 · Reply
Nickhzap
Nickhzap Aug. 8 at 1:47 AM
$ZYME sheep boy has gotten awfully quiet
2 · Reply
buyoutorbust_
buyoutorbust_ Aug. 7 at 8:52 PM
$ZYME Roughly 85-90% chances of approval give or take? The asymmetrical setup here looks lovely.
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Aug. 6 at 9:15 PM
$ZYME lot of nice tidbits in that earnings. Co is really turning into a player
1 · Reply
Mikelonggggggggg
Mikelonggggggggg Aug. 6 at 6:02 PM
$ZYME
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Aug. 5 at 6:08 PM
$ZYME
1 · Reply
copytheinsider
copytheinsider Aug. 4 at 5:35 PM
$ZYME has an FDA decision coming up on August 25 for zanidatamab. If approved, Zymeworks is eligible to receive a $250 million milestone payment from Jazz, making this one of biotech's biggest August catalysts. Do you think the FDA approves?
1 · Reply
Boris_Badenov
Boris_Badenov Aug. 3 at 9:45 PM
$ZYME JAZZ earnings release/call affirmed ready to launch GEA on or before 8/25 (PDUFA). Reported $15.4 million in Ziihera revenues for 2Q26 (compared to $6 million 2Q25).
1 · Reply
BuyingSheep
BuyingSheep Aug. 3 at 2:43 PM
$ZYME everything is green today except this turd. 💩
1 · Reply
Merlintrader
Merlintrader Jul. 31 at 6:09 PM
Zymeworks ($ZYME) Stock Hub: the $250 Million FDA Milestone, Ziihera PDUFA, Theravance Deal and the New Royalty-R&D Model https://www.merlintrader.com/zymeworks-stock-hub/
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Jul. 31 at 2:10 AM
$ZYME well...we didn't get that farmstead. It basically came down to the buyer letters...which we had one typed the other people didn't, last minute the sellers requested one so other buyers wrote one we probably should have modified ours but... I guess everything happens for a reason. Keep stacking assets in our paid off house for now and look for the next opportunity Looking for a pick me up on zyme approval
1 · Reply
buzzkiller
buzzkiller Jul. 31 at 1:25 AM
$ZYME somebody knows something....
0 · Reply
Nickhzap
Nickhzap Jul. 31 at 12:35 AM
$ZYME we will likely hear about zani approval any day now. Sheep boy will be silenced for good real soon 😊😊😊
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Jul. 30 at 12:36 AM
$ZYME sheep farmer creaming his jeans only being down 120% now
1 · Reply
BuyingSheep
BuyingSheep Jul. 29 at 2:22 PM
$ZYME welcome back to the tens very soon. 🥳
1 · Reply
Nickhzap
Nickhzap Jul. 28 at 6:47 PM
$ZYME shhhhhh 🤫🤫🤫 Can you let the adults trade in peace????
1 · Reply
BuyingSheep
BuyingSheep Jul. 28 at 2:25 PM
$ZYME another day in wonderland 🤡
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Jul. 27 at 3:42 AM
$ZYME to buy or not to buy this farmstead🤔 35 acres very secluded...wish the house was better laid out but it's just the gf and myself and a dog not a family it's manageable with the less than ideal house A lot of possibilities here I can do everything I love to do like hunting, harvesting stuff from the land like maple syrup, and just staying busy working on things around the property. Could market barn as a wedding venue people spend big bucks on that We looked at it Saturday and may put offer in tomorrow Wish zyme was a little quicker and id feel better about spending money currently
4 · Reply
Nickhzap
Nickhzap Jul. 23 at 11:39 PM
$ZYME keep loading your boat. She’s going to go gangbusters soon. Best immediate risk/ reward out there right now
0 · Reply
StarshipBlooper
StarshipBlooper Jul. 23 at 2:24 PM
$ZYME deal of the year down here
0 · Reply
Nickhzap
Nickhzap Jul. 21 at 1:53 AM
$ZYME bought another $10K today 🤑🤑🤑 mark this post please. I’ll be laughing even harder in one month
1 · Reply